• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

SPC25作为肺腺癌的一种预后及免疫相关生物标志物。

SPC25 as a prognostic and immune-related biomarker in lung adenocarcinoma.

作者信息

Liu Pan, Wang Lili, Xing Sining, Zhao Song, Yu Huiying

机构信息

Laboratory of Basic Medicine, General Hospital of Northern Theater Command, Shenyang, 110016, Liaoning, China.

Beifang Hospital of China Medical University, Shenyang, China.

出版信息

Sci Rep. 2025 Jul 21;15(1):26414. doi: 10.1038/s41598-025-09615-6.

DOI:10.1038/s41598-025-09615-6
PMID:40691691
Abstract

In the development of human cancers, alterations in the process of cell mitosis frequently play a role. In recent years, an increasing number of researchers have focused on the phenomenon of cancer resulting from kinetochore-microtubule attachment imbalance.Spindle pole body component 25 (SPC25) is essential for the organization of the spindle devices and chromosome separation. SPC25 has a significant role in the occurrence and development of malignant tumors, but its role in lung adenocarcinoma has not been established. This study utilizes the TCGA database and centrosome assembly checkpoint specialized resources to explore the molecular mechanisms of lung adenocarcinoma and its interaction with the immune system. By using the "limma" and "survival" R software packages and Venn diagram analysis, we identify differentially expressed mRNAs that are associated with lung adenocarcinoma prognosis and play a role in centrosome assembly checkpoint regulation, and determine SPC25 as the target gene. We use the "pROC" software package to draw ROC curves to evaluate its diagnostic potential, perform chi-square tests and logistic regression models to analyze its relationship with clinical pathological features. Cox regression analysis deepens our understanding of its prognostic evaluation role, and enrichment analysis reveals its biological functions and signaling pathways. We also explore the correlation between SPC25 and lung adenocarcinoma immune infiltration by combining ssGSEA and Spearman analysis. The objective of this study was to investigate the association between SPC25 and the prognosis as well as immune infiltration in lung adenocarcinoma, aiming to establish a crucial molecular foundation for early non-invasive diagnosis and immunotherapy of lung adenocarcinoma.

摘要

在人类癌症的发展过程中,细胞有丝分裂过程的改变常常发挥作用。近年来,越来越多的研究人员关注到因动粒-微管附着失衡导致癌症的现象。纺锤极体组件25(SPC25)对于纺锤体装置的组织和染色体分离至关重要。SPC25在恶性肿瘤的发生和发展中具有重要作用,但其在肺腺癌中的作用尚未明确。本研究利用TCGA数据库和中心体组装检查点专门资源,探讨肺腺癌的分子机制及其与免疫系统的相互作用。通过使用“limma”和“survival”R软件包以及维恩图分析,我们鉴定出与肺腺癌预后相关且在中心体组装检查点调节中起作用的差异表达mRNA,并确定SPC25为靶基因。我们使用“pROC”软件包绘制ROC曲线以评估其诊断潜力,进行卡方检验和逻辑回归模型分析其与临床病理特征的关系。Cox回归分析加深了我们对其预后评估作用的理解,富集分析揭示了其生物学功能和信号通路。我们还通过结合单样本基因集富集分析(ssGSEA)和Spearman分析,探讨SPC25与肺腺癌免疫浸润之间的相关性。本研究的目的是探讨SPC25与肺腺癌预后及免疫浸润之间的关联,旨在为肺腺癌的早期非侵入性诊断和免疫治疗建立关键的分子基础。

相似文献

1
SPC25 as a prognostic and immune-related biomarker in lung adenocarcinoma.SPC25作为肺腺癌的一种预后及免疫相关生物标志物。
Sci Rep. 2025 Jul 21;15(1):26414. doi: 10.1038/s41598-025-09615-6.
2
The prognostic significance and Immunomodulatory role of SCGB3A1 expression in stage I lung adenocarcinoma.SCGB3A1表达在I期肺腺癌中的预后意义及免疫调节作用
BMC Med Genomics. 2025 Jul 21;18(1):119. doi: 10.1186/s12920-025-02192-7.
3
Comprehensive analysis of RFC4 as a potential biomarker for regulating the immune microenvironment and predicting immune therapy response in lung adenocarcinoma.对RFC4作为调节肺腺癌免疫微环境和预测免疫治疗反应的潜在生物标志物的综合分析。
Front Immunol. 2025 Jun 19;16:1578243. doi: 10.3389/fimmu.2025.1578243. eCollection 2025.
4
Unraveling the role of GPCR signaling in metabolic reprogramming and immune microenvironment of lung adenocarcinoma: a multi-omics study with experimental validation.揭示GPCR信号在肺腺癌代谢重编程和免疫微环境中的作用:一项具有实验验证的多组学研究
Front Immunol. 2025 Jun 6;16:1606125. doi: 10.3389/fimmu.2025.1606125. eCollection 2025.
5
Developing a prognostic signature and characterizing the tumor microenvironment based on centrosome-related genes in lung adenocarcinoma.基于中心体相关基因构建肺腺癌预后特征并刻画肿瘤微环境
Oncol Res. 2025 Jun 26;33(7):1649-1666. doi: 10.32604/or.2025.056176. eCollection 2025.
6
MASP1 in stomach adenocarcinoma: linking diagnosis, prognosis, and tumor immunity.胃腺癌中的MASP1:连接诊断、预后和肿瘤免疫
Discov Oncol. 2025 Jun 13;16(1):1085. doi: 10.1007/s12672-025-02900-w.
7
Single-cell RNA sequencing technology was employed to construct a risk prediction model for genes associated with pyroptosis and ferroptosis in lung adenocarcinoma.采用单细胞RNA测序技术构建肺腺癌中与细胞焦亡和铁死亡相关基因的风险预测模型。
Respir Res. 2025 Jul 18;26(1):249. doi: 10.1186/s12931-025-03323-5.
8
A novel disulfidptosis-related prognostic gene signature and experimental validation identify as a novel therapeutic target in lung adenocarcinoma.一种新型的与铁死亡相关的预后基因特征及实验验证确定其为肺腺癌中的一个新型治疗靶点。
Cancer Biomark. 2025 Jan;42(1):CBM230276. doi: 10.3233/CBM-230276. Epub 2024 Feb 12.
9
Bioinformatics analysis of BTK expression in lung adenocarcinoma: implications for immune infiltration, prognostic biomarkers, and therapeutic targeting.肺腺癌中BTK表达的生物信息学分析:对免疫浸润、预后生物标志物和治疗靶点的意义
3 Biotech. 2024 Sep;14(9):215. doi: 10.1007/s13205-024-04053-z. Epub 2024 Aug 28.
10
Comprehensive pan-cancer analysis reveals NTN1 as an immune infiltrate risk factor and its potential prognostic value in SKCM.全面的泛癌分析揭示NTN1作为一种免疫浸润风险因素及其在皮肤黑色素瘤中的潜在预后价值。
Sci Rep. 2025 Jan 25;15(1):3223. doi: 10.1038/s41598-025-85444-x.

本文引用的文献

1
A comprehensive review and in silico analysis of the role of survivin (BIRC5) in hepatocellular carcinoma hallmarks: A step toward precision.生存素(BIRC5)在肝细胞癌特征中作用的全面综述及计算机模拟分析:迈向精准医学的一步
Int J Biol Macromol. 2025 Jun;311(Pt 1):143616. doi: 10.1016/j.ijbiomac.2025.143616. Epub 2025 Apr 28.
2
CRYOVATE: A Pilot Study of Lung Cancer Cryoactivation in Combination With Immunotherapy in Advanced NSCLC.CRYOVATE:晚期非小细胞肺癌中冷冻激活联合免疫疗法的一项初步研究
JTO Clin Res Rep. 2024 Oct 15;5(12):100737. doi: 10.1016/j.jtocrr.2024.100737. eCollection 2024 Dec.
3
Fibroblast growth factor receptor 1 gene (FGFR1) amplification in non-small cell lung cancer (NSCLC) by real-time PCR.
通过实时聚合酶链反应检测非小细胞肺癌(NSCLC)中纤维母细胞生长因子受体1基因(FGFR1)的扩增情况。
Caspian J Intern Med. 2024 Oct 19;16(1):66-72. doi: 10.22088/cjim.16.1.66. eCollection 2025 Winter.
4
Study on the inhibition of non-small cell lung cancer mediated by chitosan-based gene carrier delivering STAT3-shRNA.基于壳聚糖的基因载体递送STAT3-shRNA介导的非小细胞肺癌抑制研究
Int J Biol Macromol. 2025 Jan;284(Pt 2):138211. doi: 10.1016/j.ijbiomac.2024.138211. Epub 2024 Nov 29.
5
Development and validation of a radiomic prediction model for TACC3 expression and prognosis in non-small cell lung cancer using contrast-enhanced CT imaging.基于对比增强CT成像的非小细胞肺癌TACC3表达及预后的影像组学预测模型的建立与验证
Transl Oncol. 2025 Jan;51:102211. doi: 10.1016/j.tranon.2024.102211. Epub 2024 Nov 27.
6
Identification of a Novel Signature Based on Ferritinophagy-Related Genes to Predict Prognosis in Lung Adenocarcinoma: Focus on AHNAK2.基于铁蛋白自噬相关基因的新型标志物鉴定以预测肺腺癌预后:聚焦AHNAK2
Bioengineering (Basel). 2024 Oct 26;11(11):1070. doi: 10.3390/bioengineering11111070.
7
Analysis of PD1, LAG3, TIGIT, and TIM3 expression in human lung adenocarcinoma reveals a 25-gene signature predicting immunotherapy response.对人肺腺癌中PD1、LAG3、TIGIT和TIM3表达的分析揭示了一种预测免疫治疗反应的25基因特征。
Cell Rep Med. 2024 Dec 17;5(12):101831. doi: 10.1016/j.xcrm.2024.101831. Epub 2024 Nov 25.
8
Gene expression-based modeling of overall survival in Black or African American patients with lung adenocarcinoma.基于基因表达的肺腺癌黑种人或非裔美国人总生存期建模。
Front Immunol. 2024 Nov 11;15:1478491. doi: 10.3389/fimmu.2024.1478491. eCollection 2024.
9
SPC25 Activates the Warburg Effect to Inhibit Ferroptosis in Prostate Cancer Cells.SPC25 通过激活瓦博格效应抑制前列腺癌细胞中的铁死亡。
Am J Mens Health. 2024 Nov-Dec;18(6):15579883241297880. doi: 10.1177/15579883241297880.
10
How to Keep Up With Molecular Testing and Targeted Therapies in Lung Cancer.如何紧跟肺癌的分子检测和靶向治疗
JCO Oncol Pract. 2024 Nov;20(11):1471-1480. doi: 10.1200/OP.24.00230. Epub 2024 Nov 12.